Sonja Althammer on Role of CD8 and PD-L1 Biomarkers for Immunotherapy in NSCLC

Sonja Althammer, PhD
Published: Wednesday, Nov 16, 2016


Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, Munich, Bavaria, Germany, discusses a study looking to define a subgroup of patients with non–small cell lung cancer (NSCLC) who respond well to treatment with the PD-L1 inhibitor durvalumab.  
 
It was already known that PD-L1 by itself serves as biomarker to predict response to durvalumab.  However, researchers hypothesized that both CD8+ and PD-L1+ cells were critical for patient response to immunotherapies.
 
The study determined that the combination of CD8+ and PD-L1+ both correlated with response and improved overall survival with durvalumab. An independent study is planned to validate these results.
 

Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, Munich, Bavaria, Germany, discusses a study looking to define a subgroup of patients with non–small cell lung cancer (NSCLC) who respond well to treatment with the PD-L1 inhibitor durvalumab.  
 
It was already known that PD-L1 by itself serves as biomarker to predict response to durvalumab.  However, researchers hypothesized that both CD8+ and PD-L1+ cells were critical for patient response to immunotherapies.
 
The study determined that the combination of CD8+ and PD-L1+ both correlated with response and improved overall survival with durvalumab. An independent study is planned to validate these results.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x